Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
2021 Archives
Dec 20, 2021 Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of... More |
Nov 3, 2021 --Company Announces Restructuring Plan Targeting $20 Million in Reduced Expenses, To Consolidate Manufacturing Operations and Restructure the R&D Function-- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 first quarter ended September 30, 2021. "For the quarter, solid sales of several key products contributed to... More |
Oct 28, 2021 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 first quarter on Wednesday, November 3, 2021, after the market closes. Lannett... More |
Aug 30, 2021 Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, an internally developed product. Total U.S. sales of... More |
Aug 25, 2021 - Q4 Business and Financial Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 fourth quarter and full year ended June 30, 2021. "With the recently signed agreement to be the exclusive... More |
Aug 18, 2021 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 fourth quarter and full year on Wednesday, August 25, 2021, after the market closes.... More |
Jul 29, 2021 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva® Handihaler®... More |
Jul 12, 2021 Lannett Company, Inc. (NYSE: LCI) today announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product. Total U.S. sales of Fluvastatin Sodium... More |
Jun 1, 2021 Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for Fluticasone Propionate and Salmeterol... More |
May 5, 2021 Q3 Business and Financial Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 third quarter ended March 31, 2021. "In recent months, we have significantly advanced a number of strategic... More |
Apr 28, 2021 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 third quarter on Wednesday, May 5, 2021, after the market closes. Lannett management... More |
Apr 22, 2021 --Transaction Proceeds Used to Retire Company's Term Loan B Due 2022-- Lannett Company, Inc. (NYSE: LCI) today announced the closing of the $350 million aggregate principal amount of 7.750% senior secured notes due 2026 (the "Notes") in a private placement to... More |
Apr 9, 2021 Lannett Company, Inc. (NYSE: LCI) (the "Company" or "Lannett") today announced the pricing of the $350 million aggregate principal amount of 7.75% senior secured notes due 2026 (the "Notes") in a... More |
Apr 6, 2021 Lannett Company, Inc. (NYSE: LCI) (the "Company") today announced that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of senior... More |
Apr 1, 2021 Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg... More |
Mar 10, 2021 --FDA Provides Feedback on Pivotal Trial Protocol and Statistical Analysis Plan-- Lannett Company, Inc. (NYSE: LCI) today announced that it recently received feedback from the U.S. Food and Drug Administration (FDA) regarding biosimilar insulin glargine, a product the company... More |
Feb 9, 2021 --Lannett and HEC to Co-develop Insulin Aspart; Lannett Granted Exclusive US Commercialization Rights-- Lannett Company, Inc. (NYSE: LCI) today announced that it has added a new co-development agreement for biosimilar insulin aspart with its strategic alliance partners within the HEC Group of... More |
Feb 8, 2021 Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg. The company recently received... More |
Feb 3, 2021 Q2 Financial and Business Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 second quarter ended December 31, 2020. "For the fiscal 2021 second quarter, net sales exceeded our... More |
Jan 27, 2021 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 second quarter on Wednesday, February 3, 2021, after the market closes. Lannett... More |